{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T20:29:28Z","timestamp":1788121768537,"version":"build-2803163510"},"reference-count":75,"publisher":"Bentham Science Publishers Ltd.","issue":"5","funder":[{"DOI":"10.13039\/501100008347","name":"Bezmialem Vakif University scientific research","doi-asserted-by":"publisher","award":["6.2019\/19"],"award-info":[{"award-number":["6.2019\/19"]}],"id":[{"id":"10.13039\/501100008347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CHR"],"published-print":{"date-parts":[[2020,10,16]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Serum cytokine levels over the course of HIV infection usually increase\nwith immunosuppression and decrease after antiretroviral treatment (ART).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objectives:<\/jats:title>\n<jats:p>The aim of the study is to compare cytokine levels between HIV-infected patients (HIP)\nand controls and investigate the relationship between CD4+T cell count, HIV-RNA levels, and cytokine\nlevels.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The study subjects comprised ART-naive HIP (n=30) with no comorbidities and age-and\nsex-matched healthy controls. We measured levels of IL-6, IL-1\u03b2, TNF-\u03b1, and IFN-\u03b3 in serum samples\nof HIP at the beginning and at month 6 of ART and in controls.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The mean age of the study subjects was 38.7 \u00b110.3 years, with men making up 86.7% of the\nstudy subjects (n=26). IL-6, IL-1\u03b2, and TNF-\u03b1 levels were significantly higher in both ART-naive\n(p&lt;0.001, p=0.002, p=0.001) and ART-experienced HIP (p&lt;0.001) than controls. The IFN-\u03b3 level was\nlower in both ART-naive and ART-experienced HIP compared to controls (p=0.082 and p=0.002).\nThere was a positive correlation between the CD4+T cell count and serum concentration of IFN-\n\u03b3(r=0.320, p&lt;0.05). While the serum IFN-\u03b3 concentration showed a negative correlation with the HIVRNA\nlevel(r=-0.412, p&lt;0.001), the serum IL-1\u03b2, IL-6, and TNF-\u03b1 concentrations showed a positive\ncorrelation with the HIV-RNA level (r=0.349, p&lt;0.001; r:0.54, p&lt;0.001; r:0.438, p&gt;0.00).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions:<\/jats:title>\n<jats:p>Although serum concentrations of IL-6, IL-1\u03b2 and TNF-\u03b1 showed a significant decrease\nafter ART, they were still significantly higher than the controls. IFN-\u03b3 responded differently\nto ART compared to the other cytokines, indicating that it may play a distinct and important role in\nthe pathogenesis of HIV infection.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570162x18666200712174642","type":"journal-article","created":{"date-parts":[[2020,7,12]],"date-time":"2020-07-12T19:24:16Z","timestamp":1594581856000},"page":"354-361","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["The Effect of Antiretroviral Therapy on IL-6, IL-1\u03b2, TNF-\u03b1, IFN-\u03b3 Levels and their Relationship with HIV-RNA and CD4+ T Cells in HIV Patients"],"prefix":"10.2174","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1616-2162","authenticated-orcid":true,"given":"G\u00fclay","family":"Okay","sequence":"first","affiliation":[{"name":"Bezmialem Vakif University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meliha Meric","family":"Koc","sequence":"additional","affiliation":[{"name":"Bezmialem Vakif University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eray Metin","family":"Guler","sequence":"additional","affiliation":[{"name":"Bezmialem Vakif University, Faculty of Medicine, Department of Medical Biochemistry, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015feg\u00fcl","family":"Yabaci","sequence":"additional","affiliation":[{"name":"Bezmialem Vakif University, Department of Biostatistics, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abd\u00fcrrahim","family":"Kocyigit","sequence":"additional","affiliation":[{"name":"Bezmialem Vakif University, Faculty of Medicine, Department of Medical Biochemistry, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasemin","family":"Akkoyunlu","sequence":"additional","affiliation":[{"name":"Bezmialem Vakif University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","unstructured":"World Health Organization (WHO). Global Health Observatory on HIV\/AIDS Available from:"},{"key":"ref=2","author":"Sax P.E.","unstructured":"Sax P.E.; Wood B.R.;  The natural history and clinical features of HIV infection in adults and adolescents  UpToDate 2020 Available from:","journal-title":"The natural history and clinical features of HIV infection in adults and adolescents  UpToDate 2020 Available from:"},{"key":"ref=3","unstructured":"World Health Organization (WHO) Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. 2018 Available from:"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/095632020101200301","volume":"12","author":"Kedzierska K.","year":"2001","unstructured":"Kedzierska K.; Crowe S.M.; Cytokines and HIV-1: interactions and clinical implications. Antivir Chem Chemother 2001,12(3),133-150","journal-title":"Antivir Chem Chemother"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/rmv.369","volume":"13","author":"Kedzierska K.","year":"2003","unstructured":"Kedzierska K.; Crowe S.M.; Turville S.; Cunningham A.L.; The influence of cytokines, chemokines and their receptors on HIV-1 replication in monocytes and macrophages. Rev Med Virol 2003,13(1),39-56","journal-title":"Rev Med Virol"},{"key":"ref=6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00498","volume":"4: 498","author":"Roff SR","year":"2014","unstructured":"Roff SR; Noon-Song EN; Yamamoto JK;  The Significance of Interferon\u03b3 in HIV-1 Pathogenesis, Therapy, and Prophylaxis. Front Immunol  2014,4: 498"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1699-0463.1995.tb01092.x","volume":"103","author":"Belardelli F.","year":"1995","unstructured":"Belardelli F.; Role of interferons and other cytokines in the regulation of the immune response. APMIS 1995,103(3),161-179","journal-title":"APMIS"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.2174\/1570162X16666180817115830","volume":"16","year":"2018","unstructured":"D Urbano V, De Crignis E, Re MC. Host Restriction Factors and Human Immunodeficiency Virus (HIV-1): A Dynamic Interplay Involving All Phases of the Viral Life Cycle. Curr HIV Res 2018,16(3),184-207","journal-title":"Curr HIV Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.humimm.2012.03.012","volume":"73","author":"Ramaseri Sunder S.","year":"2012","unstructured":"Ramaseri Sunder S.; Hanumanth S.R.; Nagaraju R.T.; IL-10 high producing genotype predisposes HIV infected individuals to TB infection. Hum Immunol 2012,73(6),605-611","journal-title":"Hum Immunol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1089\/aid.2006.22.757","volume":"22","author":"Norris P.J.","year":"2006","unstructured":"Norris P.J.; Pappalardo B.L.; Custer B.; Spotts G.; Hecht F.M.; Busch M.P.; Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection. AIDS Res Hum Retroviruses 2006,22(8),757-762","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/QAI.0000000000001181","volume":"74","author":"Thobakgale C","year":"2017","unstructured":"Thobakgale C; Naidoo K; McKinnon LR; Interleukin 1-Beta (IL-1\u03b2) Production by Innate Cells Following TLR Stimulation Correlates With TB Recurrence in ART-Treated HIV-Infected Patients. J Acquir Immune Defic Syndr 2017,74(2),213-20"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/j.1468-1293.2007.00445.x","volume":"8","author":"French M.","year":"2007","unstructured":"French M.; Keane N.; McKinnon E.; Phung S.; Price P.; Susceptibility to opportunistic infections in HIV-infected patients with increased CD4 T-cell counts on antiretroviral therapy may be predicted by markers of dysfunctional effector memory CD4 T cells and B cells. HIV Med 2007,8(3),148-155","journal-title":"HIV Med"},{"key":"ref=13","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4128398","volume":"2017","author":"Akase I.E.","year":"2017","unstructured":"Akase I.E.; Musa B.O.P.; Obiako R.O.; Ahmad Elfulatiy A.; Mohammed A.A.; Immune Dysfunction in HIV: A Possible Role for Pro and Anti-Inflammatory Cytokines in HIV Staging. J Immunol Res 2017,2017","journal-title":"J Immunol Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/infdis\/jiu254","volume":"210","author":"Tenorio A.R.","year":"2014","unstructured":"Tenorio A.R.; Zheng Y.; Bosch R.J.; Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS defining morbid events during suppressive antiretroviral treatment. J Infect Dis 2014,210(8),1248-1259","journal-title":"J Infect Dis"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2174\/1570162X14666160414111554","volume":"14","author":"Bellissimo F.","year":"2016","unstructured":"Bellissimo F.; Pinzone M.R.; Celesia B.M.; Cacopardo B.; Nunnari G.; Baseline CD4\/CD8 T-Cell Ratio Predicts Prompt Immune Restoration Upon cART Initiation. Curr HIV Res 2016,14(6),491-496","journal-title":"Curr HIV Res"},{"key":"ref=16","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.000844","volume":"3","author":"Nordell A.D.","year":"2014","unstructured":"Nordell A.D.; McKenna M.; Borges \u00c1.H.; Duprez D.; Neuhaus J.; Neaton J.D.; INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc 2014,3(3)","journal-title":"J Am Heart Assoc"},{"key":"ref=17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050203","volume":"5","author":"Kuller L.H.","year":"2008","unstructured":"Kuller L.H.; Tracy R.; Belloso W.; INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008,5(10)","journal-title":"PLoS Med"},{"key":"ref=18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024243","volume":"7","author":"Ledwaba L.","year":"2012","unstructured":"Ledwaba L.; Tavel J.A.; Khabo P.; Project Phidisa Biomarkers Team. Pre-ART levels of inflammation and coagulation markers are strong predictors of death in a South African cohort with advanced HIV disease. PLoS One 2012,7(3)","journal-title":"PLoS One"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/infdis\/jiu238","volume":"210","author":"Hunt P.W.","year":"2014","unstructured":"Hunt P.W.; Sinclair E.; Rodriguez B.; Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis 2014,210(8),1228-1238","journal-title":"J Infect Dis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/QAI.0b013e3181b033ab","volume":"52","author":"Bedimo R.J.","year":"2009","unstructured":"Bedimo R.J.; McGinnis K.A.; Dunlap M.; Rodriguez-Barradas M.C.; Justice A.C.; Incidence of non-AIDS-defining malignancies in HIV infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr 2009,52(2),203-208","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"728","DOI":"10.7326\/0003-4819-148-10-200805200-00005","volume":"148","author":"Patel P.","year":"2008","unstructured":"Patel P.; Hanson D.L.; Sullivan P.S.; Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008,148(10),728-736","journal-title":"Ann Intern Med"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1097\/QAD.0b013e328339192f","volume":"24","author":"Lang S.","year":"2010","unstructured":"Lang S.; Mary-Krause M.; Cotte L.; French Hospital Database on HIV-ANRS CO4. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS 2010,24(8),1228-1230","journal-title":"AIDS"},{"key":"ref=23","doi-asserted-by":"publisher","DOI":"10.3390\/v11030200","volume":"11","author":"Zicari S.","year":"2019","unstructured":"Zicari S.; Sessa L.; Cotugno N.; Immune Activation, Inflammation, and Non-AIDS Co-Morbidities in HIV-Infected Patients under Long-Term ART. Viruses 2019,11(3)","journal-title":"Viruses"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40265-016-0546-7","volume":"76","author":"Hsu D.C.","year":"2016","unstructured":"Hsu D.C.; Sereti I.; Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection. Drugs 2016,76(5),533-549","journal-title":"Drugs"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","volume":"370","author":"Grulich A.E.","year":"2007","unstructured":"Grulich A.E.; van Leeuwen M.T.; Falster M.O.; Vajdic C.M.; Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007,370(9581),59-67","journal-title":"Lancet"},{"key":"ref=26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044454","volume":"7","author":"Duprez D.A.","year":"2012","unstructured":"Duprez D.A.; Neuhaus J.; Kuller L.H.;  INSIGHT SMART Study Group. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 2012,7(9)","journal-title":"PLoS One"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/cid\/cis489","volume":"55","author":"Lang S.","year":"2012","unstructured":"Lang S.; Mary-Krause M.; Simon A.; French Hospital Database on HIV (FHDH)\u2013ANRS CO4. HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals. Clin Infect Dis 2012,55(4),600-607","journal-title":"Clin Infect Dis"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1086\/652749","volume":"201","author":"Neuhaus J.","year":"2010","unstructured":"Neuhaus J.; Jacobs D.R.; Baker J.V.; Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010,201(12),1788-1795","journal-title":"J Infect Dis"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/QAI.0b013e3181e66216","volume":"55","author":"Tien PC","year":"2010","unstructured":"Tien PC; Choi AI; Zolopa AR; Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr 2010,55(3),316-22"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/cid\/cis406","volume":"55","author":"Armah K.A.","year":"2012","unstructured":"Armah K.A.; McGinnis K.; Baker J.; HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis 2012,55(1),126-136","journal-title":"Clin Infect Dis"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1093\/infdis\/jir134","volume":"203","author":"Boulware D.R.","year":"2011","unstructured":"Boulware D.R.; Hullsiek K.H.; Puronen C.E.; INSIGHT Study Group Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis 2011,203(11),1637-1646","journal-title":"J Infect Dis"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1097\/QAD.0b013e32834c4ac1","volume":"25","author":"Hunt P.W.","year":"2011","unstructured":"Hunt P.W.; Cao H.L.; Muzoora C.; Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS 2011,25(17),2123-2131","journal-title":"AIDS"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1086\/605890","volume":"200","author":"French M.A.","year":"2009","unstructured":"French M.A.; King M.S.; Tschampa J.M.; da Silva B.A.; Landay A.L.; Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J Infect Dis 2009,200(8),1212-1215","journal-title":"J Infect Dis"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/QAD.0000000000000545","volume":"29","author":"Wada N.I.","year":"2015","unstructured":"Wada N.I.; Jacobson L.P.; Margolick J.B.; The effect of HAART induced HIV suppression on circulating markers of inflammation and immune activation. AIDS 2015,29(4),463-471","journal-title":"AIDS"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1097\/QAD.0b013e3283389dfa","volume":"24","author":"Palella F.J.","year":"2010","unstructured":"Palella F.J.; Gange S.J.; Benning L.; Inflammatory biomarkers and abacavir use in the Women\u2019s Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS 2010,24(11),1657-1665","journal-title":"AIDS"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3851\/IMP2681","volume":"19","author":"Wohl D.A.","year":"2014","unstructured":"Wohl D.A.; Arnoczy G.; Fichtenbaum C.J.; Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study. Antivir Ther (Lond) 2014,19(2),141-147","journal-title":"Antivir Ther (Lond)"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1097\/QAD.0b013e32833a608a","volume":"24","author":"Mart\u00ednez E.","year":"2010","unstructured":"Mart\u00ednez E.; Larrousse M.; Llibre J.M.; SPIRAL Study Group Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010,24(11),1697-1707","journal-title":"AIDS"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/23744235.2019.1629008","volume":"51","author":"Calza L.","year":"2019","unstructured":"Calza L.; Colangeli V.; Borderi M.; Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver disease. Infect Dis (Lond) 2019,51(8),593-601","journal-title":"Infect Dis (Lond)"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1089\/vim.2010.0065","volume":"23","author":"Watanabe D.","year":"2010","unstructured":"Watanabe D.; Uehira T.; Yonemoto H.; Sustained high levels of serum interferon-\u03b3 during HIV-1 infection: a specific trend different from other cytokines. Viral Immunol 2010,23(6),619-625","journal-title":"Viral Immunol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/hiv.12600","volume":"19","author":"Ryom L.","year":"2018","unstructured":"Ryom L.; Boesecke C.; Bracchi M.; EACS Governing Board. Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0. HIV Med 2018,19(5),309-315","journal-title":"HIV Med"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.7326\/0003-4819-119-1-199307010-00010","volume":"119","author":"Laurence J.","year":"1993","unstructured":"Laurence J.; \n                        T-cell subsets in health, infectious disease, and idiopathic CD4+ T lymphocytopenia. Ann Intern Med\n                     1993,119(1),55-62"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3851\/IMP2093","volume":"17","author":"Bastard J.P.","year":"2012","unstructured":"Bastard J.P.; Souli\u00e9 C.; Fellahi S.; Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients. Antivir Ther (Lond) 2012,17(5),915-919","journal-title":"Antivir Ther (Lond)"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/COH.0000000000000019","volume":"9","author":"Funderburg N.T.","year":"2014","unstructured":"Funderburg N.T.; Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients. Curr Opin HIV AIDS 2014,9(1),80-86","journal-title":"Curr Opin HIV AIDS"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1160\/TH10-04-0233","volume":"104","author":"Jong E.","year":"2010","unstructured":"Jong E.; Louw S.; van Gorp E.C.M.; Meijers J.C.M.; ten Cate H.; Jacobson B.F.; The effect of initiating combined antiretroviral therapy on endothelial cell activation and coagulation markers in South African HIV-infected individuals. Thromb Haemost 2010,104(6),1228-1234","journal-title":"Thromb Haemost"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2174\/1570162X113119990041","volume":"11","author":"Mamadou D.","year":"2013","unstructured":"Mamadou D.; Yu-Huang Z.; Xia C.; HIV DNA and immune alteration during successful HAART. Curr HIV Res 2013,11(4),255-262","journal-title":"Curr HIV Res"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/QAI.0b013e3181685727","volume":"48","author":"Reingold J.","year":"2008","unstructured":"Reingold J.; Wanke C.; Kotler D.; Association of HIV infection and HIV\/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr 2008,48(2),142-148","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216680","volume":"14","author":"Wang R.J.","year":"2019","unstructured":"Wang R.J.; Moore J.; Moisi D.; HIV infection is associated with elevated biomarkers of immune activation in Ugandan adults with pneumonia. PLoS One 2019,14(5)","journal-title":"PLoS One"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/QAI.0000000000000954","volume":"72","author":"So-Armah K.A.","year":"2016","unstructured":"So-Armah K.A.; Tate J.P.; Chang C.H.; VACS Project Team. Do Biomarkers of Inflammation, Monocyte Activation, and Altered Coagulation Explain Excess Mortality Between HIV Infected and Uninfected People? J Acquir Immune Defic Syndr 2016,72(2),206-213","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1086\/314829","volume":"180","author":"van Gorp E.C.","year":"1999","unstructured":"van Gorp E.C.; Suharti C.; ten Cate H.; Review: infectious diseases and coagulation disorders. J Infect Dis 1999,180(1),176-186","journal-title":"J Infect Dis"},{"key":"ref=50","first-page":"168","volume":"7","author":"Connolly NC","year":"2005","unstructured":"Connolly NC; Riddler SA; Rinaldo CR;  Proinflammatory cytokines in HIV disease-a review and rationale for new therapeutic approaches AIDS Rev 2005,7(3),168-80","journal-title":"Proinflammatory cytokines in HIV disease-a review and rationale for new therapeutic approaches AIDS Rev"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/infdis\/jix666","volume":"218","year":"2018","unstructured":"Angelidou K, Hunt PW, Landay AL, et al. Changes in Inflammation but Not in T-Cell Activation Precede Non-AIDS-Defining Events in a Case-Control Study of Patients on Long-term Antiretroviral Therapy. J Infect Dis 2018,218(2),239-48"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/infdis\/jiw148","volume":"214","author":"Prendergast A.J.","year":"2016","unstructured":"Prendergast A.J.; Szubert A.J.; Berejena C.; ARROW Trial Team. Baseline Inflammatory Biomarkers Identify Subgroups of HIV-Infected African Children With Differing Responses to Antiretroviral Therapy. J Infect Dis 2016,214(2),226-236","journal-title":"J Infect Dis"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"98","DOI":"10.2174\/1570162X12666141202125016","volume":"13","author":"Mahajan S.D.","year":"2015","unstructured":"Mahajan S.D.; Gaekwad A.; Pawar J.; Cardiac morbidity in an HIV-1 lipodystrophy patient cohort expressing the TNF-\u03b1-238 G\/A single nucleotide gene polymorphism. Curr HIV Res 2015,13(2),98-108","journal-title":"Curr HIV Res"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/QCO.0000000000000510","volume":"32","author":"Peterson TE","year":"2019","unstructured":"Peterson TE; Baker JV;  Assessing inflammation and its role in comorbidities among persons living with HIV Curr Opin Infect Dis 2019,32(1),8-15","journal-title":"Assessing inflammation and its role in comorbidities among persons living with HIV Curr Opin Infect Dis"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S2055-6640(20)30303-4","volume":"3","author":"Manion M.","year":"2017","unstructured":"Manion M.; Andrade B.B.; DerSimonian R.; Country of residence is associated with distinct inflammatory biomarker signatures in HIV-infected patients. J Virus Erad 2017,3(1),24-33","journal-title":"J Virus Erad"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2217\/bmm.11.15","volume":"5","author":"Lichtfuss G.F.","year":"2011","unstructured":"Lichtfuss G.F.; Hoy J.; Rajasuriar R.; Kramski M.; Crowe S.M.; Lewin S.R.; Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection. Biomarkers Med 2011,5(2),171-186","journal-title":"Biomarkers Med"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","volume":"371","author":"Sabin C.A.","year":"2008","unstructured":"Sabin C.A.; Worm S.W.; Weber R.; D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008,371(9622),1417-1426","journal-title":"Lancet"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"F17","DOI":"10.1097\/QAD.0b013e32830fe35e","volume":"22","year":"2008","unstructured":"Strategies for Management of Anti-Retroviral Therapy\/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008,22(14),F17-F24","journal-title":"AIDS"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2174\/1570162X1401151102143222","volume":"14","author":"Calza L.","year":"2016","unstructured":"Calza L.; Magistrelli E.; Danese I.; Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz. Curr HIV Res 2016,14(1),61-70","journal-title":"Curr HIV Res"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1097\/00002030-200009290-00023","volume":"14","author":"Torre D.","year":"2000","unstructured":"Torre D.; Speranza F.; Martegani R.; Circulating levels of IL-18 in adult and paediatric patients with HIV-1 infection. AIDS 2000,14(14),2211-2212","journal-title":"AIDS"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1600-0463.2006.apm_108.x","volume":"114","author":"Orsilles M.A.","year":"2006","unstructured":"Orsilles M.A.; Pieri E.; Cooke P.; Caula C.; IL-2 and IL-10 serum levels in HIV-1-infected patients with or without active antiretroviral therapy. APMIS 2006,114(1),55-60","journal-title":"APMIS"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1046\/j.1365-2249.2003.02179.x","volume":"132","author":"Stylianou E","year":"2003","unstructured":"Stylianou E; Bjerkeli V; Yndestad A; Raised serum levels of interleukin-18 is associated with disease progression and may contribute to virological treatment failure in HIV-1-infected patients. Clin Exp Immunol 2003,132(3),462-6"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.clim.2006.07.008","volume":"121","author":"Akerele T.","year":"2006","unstructured":"Akerele T.; Galatowicz G.; Bunce C.; Calder V.; Lynn W.A.; Lightman S.; Normalized CD8+ but not CD4+ lymphocyte IL-2 expression is associated with early treatment with highly active antiretroviral therapy. Clin Immunol 2006,121(2),191-197","journal-title":"Clin Immunol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1086\/592716","volume":"198","author":"Benito J.M.","year":"2008","unstructured":"Benito J.M.; L\u00f3pez M.; Lozano S.; Gonz\u00e1lez-Lahoz J.; Soriano V.; Down-regulation of interleukin-7 receptor (CD127) in HIV infection is associated with T cell activation and is a main factor influencing restoration of CD4(+) cells after antiretroviral therapy. J Infect Dis 2008,198(10),1466-1473","journal-title":"J Infect Dis"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"10319","DOI":"10.1128\/JVI.75.21.10319-10325.2001","volume":"75","author":"Llano A","year":"2001","unstructured":"Llano A; Barretina J; Guti\u00e9rrez A; Interleukin-7 in plasma correlates with CD4 T-cell depletion and may be associated with emergence of syncytium-inducing variants in human immunodeficiency virus type 1-positive individuals. J Virol 2001,75(21),10319-25"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1046\/j.1365-2249.1999.00865.x","volume":"116","author":"Stylianou E","year":"1999","unstructured":"Stylianou E; Aukrust P; Kvale D; M\u00fcller F; Fr\u00f8land SS;  IL-10 in HIV infection: increasing serum IL-10 levels with disease progression-- down-regulatory effect of potent anti-retroviral therapy. Clin Exp Immunol  1999,116(1),115-20"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2174\/157016207780636524","volume":"5","author":"Almeida M.","year":"2007","unstructured":"Almeida M.; Cordero M.; Almeida J.; Orfao A.; Abnormal cytokine production by circulating monocytes and dendritic cells of myeloid origin in ART-treated HIV-1+ patients relates to CD4+ T-cell recovery and HCV co-infection. Curr HIV Res 2007,5(3),325-336","journal-title":"Curr HIV Res"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/QAD.0b013e32834273ad","volume":"25","author":"Regidor DL","year":"2011","unstructured":"Regidor DL; Detels R; Breen EC; Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation. AIDS 2011,25(3),303-14"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12879-018-3643-2","volume":"19","author":"Watanabe D.","year":"2019","unstructured":"Watanabe D.; Uehira T.; Suzuki S.; Clinical characteristics of HIV-1-infected patients with high levels of plasma interferon-\u03b3: a multicenter observational study. BMC Infect Dis 2019,19(1),11","journal-title":"BMC Infect Dis"},{"key":"ref=70","first-page":"261","volume":"91","author":"Twizerimana A.P.","year":"2014","unstructured":"Twizerimana A.P.; Mwatha J.; Musabyimana J.P.; Immunological profiles in HIV positive patients following HAART initiation in Kigali, Rwanda. East Afr Med J 2014,91(8),261-266","journal-title":"East Afr Med J"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1089\/aid.2006.0228","volume":"23","author":"Sadeghi M.","year":"2007","unstructured":"Sadeghi M.; S\u00fcsal C.; Daniel V.; Short communication: decreasing soluble CD30 and increasing IFN-gamma plasma levels are indicators of effective highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2007,23(7),886-890","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1089\/aid.2012.0275","volume":"29","author":"Yao Y.","year":"2013","unstructured":"Yao Y.; Luo Y.; He Y.; The effect of a year of highly active antiretroviral therapy on immune reconstruction and cytokines in HIV\/AIDS patients. AIDS Res Hum Retroviruses 2013,29(4),691-697","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/jmv.20558","volume":"78","author":"Sindhu S.","year":"2006","unstructured":"Sindhu S.; Toma E.; Cordeiro P.; Ahmad R.; Morisset R.; Menezes J.; Relationship of in vivo and ex vivo levels of TH1 and TH2 cytokines with viremia in HAART patients with and without opportunistic infections. J Med Virol 2006,78(4),431-439","journal-title":"J Med Virol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/j.1365-2249.2004.02583.x","volume":"137","author":"Resino S.","year":"2004","unstructured":"Resino S.; Gal\u00e1n I.; P\u00e9rez A.; HIV-infected children with moderate\/severe immune-suppression: changes in the immune system after highly active antiretroviral therapy. Clin Exp Immunol 2004,137(3),570-577","journal-title":"Clin Exp Immunol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/0167-5699(94)90220-8","volume":"15","author":"Clerici M.","year":"1994","unstructured":"Clerici M.; Shearer G.M.; The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today 1994,15(12),575-581","journal-title":"Immunol Today"}],"container-title":["Current HIV Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/183681","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/183681\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/183681","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T15:43:32Z","timestamp":1615391012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/183681\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,16]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10,16]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570162x18666200712174642","relation":{},"ISSN":["1570-162X"],"issn-type":[{"value":"1570-162X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,16]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-04-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}